Organization (Academic)
Third Military Medical University
ClinicalTrials.gov lists Third Military Medical University as lead sponsor of 82 trials. It has 11 active development programs and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Third Military Medical University: 82 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (82)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 13 |
| Diabetes Mellitus | 12 |
| Hypertension | 11 |
| Hyperaldosteronism | 9 |
| Colorectal Neoplasms | 7 |
Showing 5 of 82 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 6 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 6 |
| 2021 | 6 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 9 |
| 2017 | 8 |
Showing 10 of 22 years.
Prediction, not a registry value: median of 34 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 27 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (11)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SITAGLIPTIN | Diabetes Mellitus | Phase 3 | 1 |
| SITAGLIPTIN | Diabetes Mellitus, Type 2 | Phase 3 | 1 |
| Canagliflozin | Diabetes Mellitus | Phase 3 | 1 |
| Canagliflozin | Diabetes Mellitus, Type 2 | Phase 3 | 1 |
| FMT capsule | Autism Spectrum Disorder | Not reported | 1 |
Showing 5 of 11 active programs.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| LIRAGLUTIDE | 3 |
| Candesartan | 2 |
| Amlodipine | 2 |
| Amlodipine besylate combined Spironolactone | 1 |
| Candesartan plus Metformin | 1 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 79% hit target (n=14) | 25% on time (n=12) |
Journals published in (112)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| JAMA | 7 |
| The New England journal of medicine | 7 |
| Gastroenterology | 4 |
| PloS one | 4 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 3 |
Showing 5 of 112 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 1 | 2025-09-02 |
Organization relationships (15)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Shanghai Zhongshan Hospital | Co sponsors trial with | 2 |
| Guangzhou Institute of Respiratory Disease | Co sponsors trial with | 1 |
| Nanjing PLA General Hospital | Co sponsors trial with | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Co sponsors trial with | 1 |
| People's Hospital of Anshun City of Guizhou Province | Co sponsors trial with | 1 |
Showing 5 of 15 relationships.
Latest dated events (105)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 105 events.
Biomarker capability evidence (69)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| AMN | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 69 evidence rows.
Biomarkers this organization publishes on (730)
Shown in this order: most publications first.
Showing 5 of 730 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.